[Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities]

Area of Science:

• Hematology
• Dermatology
• Oncology

Background:

• Primary cutaneous large B-cell lymphomas (PCBLT), EBV-positive DLBCL, NOS, and PCIVLBL are cutaneous lymphomas with challenging prognoses.
• Distinguishing these from indolent lymphomas or other skin conditions is crucial for patient outcomes.
• R-CHOP immunotherapy and polychemotherapy have improved diffuse large B-cell lymphoma prognosis.

Purpose of the Study:

• To review the clinical and histological complexities of PCBLT, EBV+ DLBCL, NOS, and PCIVLBL.
• To discuss the impact of immunosenescence on EBV+ DLBCL, NOS pathogenesis in the elderly.
• To highlight the current therapeutic landscape and challenges in managing these rare cutaneous lymphomas.

Main Methods:

• Review of current literature on PCBLT, EBV+ DLBCL, NOS, and PCIVLBL.
• Analysis of prognostic factors and treatment outcomes.
• Discussion of diagnostic challenges and therapeutic decision-making.

Main Results:

• PCBLT, EBV+ DLBCL, NOS, and PCIVLBL present with variable prognoses, with EBV+ DLBCL, NOS being less favorable in the elderly.
• PCIVLBL has a significant risk of systemic progression (one-third of cases).
• EBV-positive mucocutaneous ulcer, a new category, shows a self-limiting course and responds to conservative therapy.

Conclusions:

• Individualized treatment strategies, ideally discussed in interdisciplinary tumor conferences, are essential for PCBLT management.
• The rarity of these conditions necessitates further research for evidence-based therapy recommendations.
• Understanding immunosenescence and disease-specific characteristics is key to improving patient care.